Cited by 230Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Long-term Course and Effectiveness of Combination Therapy in Alzheimer Disease

Open access

Atri, Alireza, Shaughnessy, Lynn W., Locascio, Joseph J., Growdon, John H.·2008·Alzheimer Disease & Associated Disorders

DOI 10.1097/wad.0b013e31816653bcPMC PMC2718545

Open this paper in CoChat — free account

Abstract

OBJECTIVE: To compare the real-world clinical effectiveness and long-term clinical trajectory in patients with Alzheimer disease (AD) treated with combination (COMBO) therapy consisting of cholinesterase-inhibitor (CI) plus memantine (MEM) versus CI alone versus no treatment with either. METHODS: Three hundred eighty-two subjects with probable AD underwent serial clinical evaluations at a memory disorders unit. Cognition was assessed by the Information-Memory-Concentration subscale of the Blessed Dementia Scale (BDS) and function was assessed by the Weintraub Activities of Daily Living Scale (ADL) at 6-month intervals. One hundred forty-four subjects received standard care without CI or MEM (NO-RX), 122 received CI monotherapy, and 116 received COMBO therapy with CI plus MEM. Mean follow-up was 30 months (4.1 visits) and mean cumulative medication treatment time was 22.5 months. Rates of decline were analyzed using mixed-effects regression models, and Cohen's d effect sizes were calculated annually for years 1 to 4. RESULTS: Covarying for baseline scores, age, education, and duration of illness, the COMBO group had significantly lower mean annualized rates of deterioration in BDS and ADL scores compared with the CI (P<0.001; Cohen's dBDS=0.10-0.34 and dADL=0.23-0.46 at 1 to 2 y) and NO-RX groups (P<0.001; Cohen's dBDS=0.56-0.73 and dADL=0.32-0.48 at 1 to 2 y). For the COMBO group, Cohen's d effect sizes increased with treatment duration. Similar comparisons significantly favored the CI over the NO-RX group on the BDS. CONCLUSIONS: COMBO therapy slows cognitive and functional decline in AD compared with CI monotherapy and no treatment. These benefits had small-to-medium effect sizes that increased with time on treatment and were sustained for years.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/wad.0b013e31816653bc

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Analysis of Longitudinal Data
Everitt, B. S. (2001) · Psychology Press eBooks · doi:10.4324/9781410605542-11 · Cited by 6,877
The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects
Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117
Akaike's Information Criterion in Generalized Estimating Equations
Pan, W. (2001) · Biometrics · doi:10.1111/j.0006-341x.2001.00120.x · Cited by 2,545
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Generalized Estimating Equations
Hardin, J. W., & Hilbe, J. M. (2002) · doi:10.1201/9781420035285 · Cited by 1,766

Show all 54 references

Sorted by citations

The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
The Alzheimer’s Disease Clinical Spectrum
Atri, A. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.009 · Cited by 623
“Persistence, higher dosage (in later dementia stages), and duration of treatment are associated with better outcomes, even in those with advanced dementia.(92,95,114,115,130)”
Self-citation
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 573
Alzheimer's disease, β‐amyloid, glutamate, NMDA receptors and memantine – searching for the connections
Danysz, W., & Parsons, C. G. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02057.x · Cited by 500
Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
Parsons, C. G., Danysz, W., Dekundy, A., & Pulte, I. (2013) · Neurotoxicity Research · doi:10.1007/s12640-013-9398-z · Cited by 346
Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies
Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331
Memantine for dementia.
McShane, R., Westby, M. J., Roberts, E., Minakaran, N., Schneider, L., Farrimond, L. E., Maayan, N., Ware, J., & Debarros, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub6 · Cited by 310
Current and future treatments in Alzheimer’s disease
Atri, A. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1678581 · Cited by 309
Self-citation
A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder
Mahableshwarkar, A. R., Zajecka, J., Jacobson, W., Chen, Y., & Keefe, R. S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.52 · Cited by 307
Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management
Singh, B., Day, C. M., Abdella, S., & Garg, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.047 · Cited by 256
Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer’s Disease
Noetzli, M., & Eap, C. B. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0038-9 · Cited by 230
Combination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217
Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer’s Disease and Related Dementias and Strategic Implications for Stakeholders
El-Hayek, Y. H., Wiley, R. E., Khoury, C. P., Daya, R. P., Ballard, C., Evans, A. R., Karran, M., Molinuevo, J. L., Norton, M., & Atri, A. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-190426 · Cited by 216
Self-citation
Folic Acid Supplementation Mitigates Alzheimer’s Disease by Reducing Inflammation: A Randomized Controlled Trial
Chen, H., Liu, S., Ji, L., Wu, T., Ji, Y., Zhou, Y., Zheng, M., Zhang, M., Xu, W., & Huang, G. (2016) · Mediators of Inflammation · doi:10.1155/2016/5912146 · Cited by 202
Cognitive and Behavioral Neurology
Finger, E. C., & Daffner, K. R. (2011) · Springer eBooks · doi:10.1007/978-0-387-88555-1_8 · Cited by 201
Amyloid β, Glutamate, Excitotoxicity in Alzheimer's Disease: Are We on the Right Track?
Esposito, Z., Belli, L., Toniolo, S., Sancesario, G., Bianconi, C., & Martorana, A. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12095 · Cited by 215
Combination Therapy in Alzheimer???s Disease: A Review of Current Evidence
Schmitt, B., Bernhardt, T., Moeller, H.-J., Heuser, I., & Fr??lich, L. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00001 · Cited by 182
Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease
Rountree, S. D., Chan, W., Pavlik, V. N., Darby, E. J., Siddiqui, S., & Doody, R. S. (2009) · Alzheimers Res Ther · doi:10.1186/alzrt7 · Cited by 181
Alzheimer's disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners.
Wollen, K. A. (2010) · PubMed · Cited by 170
Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias
Grossberg, G., & Thomas, S. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s6666 · Cited by 151
In the Information Age, do dementia caregivers get the information they need? Semi-structured interviews to determine informal caregivers’ education needs, barriers, and preferences
Peterson, K., Hahn, H., Lee, A. J., Madison, C. A., & Atri, A. (2016) · BMC Geriatrics · doi:10.1186/s12877-016-0338-7 · Cited by 144
Self-citation
EFNS ‐ ENS / EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease
Schmidt, R., Hofer, E., Bouwman, F. H., Buerger, K., Cordonnier, C., Fladby, T., Galimberti, D., Georges, J., Heneka, M. T., Hort, J., et al. (2015) · European Journal of Neurology · doi:10.1111/ene.12707 · Cited by 140
Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial
Jia, Y., Zhang, X., Yu, J., Han, J., Yu, T., Shi, J., Zhao, L., & Nie, K. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-2064-x · Cited by 138
Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer’s Disease: Are Irreversible Inhibitors the Future?
Moss, D. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103438 · Cited by 138
The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer’s Disease
Deardorff, W. J., Feen, E. S., & Grossberg, G. T. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0273-x · Cited by 136
The Effectiveness and Safety of Acupuncture for Patients With Alzheimer Disease
Zhou, J. W., Peng, W., Xu, M., Li, W., & Liu, Z. (2015) · Medicine · doi:10.1097/md.0000000000000933 · Cited by 128
Predicting progression of Alzheimer's disease
Doody, R. S., Pavlik, V., Massman, P. J., Rountree, S. D., Darby, E. J., & Chan, W. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt25 · Cited by 128
Network pharmacology-based study on the mechanism of action for herbal medicines in Alzheimer treatment
Fang, J., Wang, L., Wu, T., Yang, C., Gao, L., Cai, H., Liu, J., Fang, S., Chen, Y., Tan, W., et al. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.11.034 · Cited by 127
Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy
Atri, A., Molinuevo, J. L., Lemming, O., Wirth, Y., Pulte, I., & Wilkinson, D. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt160 · Cited by 126
Self-citation
A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease
Deardorff, W. J., & Grossberg, G. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86463 · Cited by 125
An Overview of Longitudinal Data Analysis Methods for Neurological Research
Locascio, J. J., & Atri, A. (2011) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000330228 · Cited by 122
Self-citation
Current therapeutic targets for the treatment of Alzheimer’s disease
Grill, J. D., & Cummings, J. L. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.29 · Cited by 123
From Single Target to Multitarget/Network Therapeutics in Alzheimer’s Therapy
Zheng, H., Fridkin, M., & Youdim, M. B. H. (2014) · Pharmaceuticals · doi:10.3390/ph7020113 · Cited by 121
Slowing the progression of Alzheimer’s disease; what works?
Nelson, L., & Tabet, N. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.07.002 · Cited by 117
Benefits of combined cholinesterase inhibitor and memantine treatment in moderate–severe Alzheimer's disease
Gauthier, S. G., & Molinuevo, J. L. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.11.005 · Cited by 111
Present Algorithms and Future Treatments for Alzheimer’s Disease
Grossberg, G. T., Tong, G., Burke, A. D., & Tariot, P. N. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180903 · Cited by 111
Update on the use of memantine in Alzheimer’s disease
van Marum, R. J. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s4048 · Cited by 108
Effectiveness of antidementia drugs in delaying Alzheimer's disease progression
Rountree, S. D., Atri, A., Lopez, O. L., & Doody, R. S. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.01.002 · Cited by 97
Self-citation
Combination Therapy for Alzheimerʼs Disease
Patel, L., & Grossberg, G. T. (2011) · Drugs & Aging · doi:10.2165/11591860-000000000-00000 · Cited by 95
Alzheimer’s disease and its treatment–yesterday, today, and tomorrow
Kim, A. Y., Jerdi, S. A., MacDonald, R., & Triggle, C. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399121 · Cited by 99
Memantine
McKeage, K. (2009) · CNS Drugs · doi:10.2165/11201020-000000000-00000 · Cited by 85
Predictors of long-term cognitive outcome in Alzheimer's disease
Wattmo, C., Wallin, Å. K., Londos, E., & Minthon, L. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt85 · Cited by 81
Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis
Atri, A., Hendrix, S. B., Pejović, V., Hofbauer, R. K., Edwards, J., Molinuevo, J. L., & Graham, S. M. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0109-2 · Cited by 78
Self-citation
Current pharmacotherapy and putative disease-modifying therapy for Alzheimer’s disease
Kulshreshtha, A., & Piplani, P. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2625-7 · Cited by 76
Efficacy of Memantine, Donepezil, or Their Association in Moderate‐Severe Alzheimer’s Disease: A Review of Clinical Trials
Molino, I., Colucci, L., Fasanaro, A. M., Traini, E., & Amenta, F. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/925702 · Cited by 73
Factors that influence survival in a probable Alzheimer disease cohort
Rountree, S. D., Chan, W., Pavlik, V., Darby, E. J., & Doody, R. S. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt119 · Cited by 72
Meaningful benefits: A framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Assunção, S. S., Sperling, R. A., Ritchie, C., Kerwin, D. R., Aisen, P. S., Lansdall, C., Atri, A., & Cummings, J. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00984-y · Cited by 71
Self-citation
α7 Nicotinic ACh Receptors as a Ligand-Gated Source of Ca2+ Ions: The Search for a Ca2+ Optimum
Uteshev, V. V. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2888-2_27 · Cited by 73
Memantine ER/Donepezil: A Review in Alzheimer’s Disease
Greig, S. L. (2015) · CNS Drugs · doi:10.1007/s40263-015-0287-2 · Cited by 69
Memantine in dementia: a review of the current evidence
Herrmann, N., Li, A., & Lanctôt, K. L. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.558006 · Cited by 71
A review of the effects of memantine on clinical progression in Alzheimer's disease
Wilkinson, D. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2788 · Cited by 74
Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease
Baseman, A. S., Häger, K., Nye, J. S., Brashear, R. H., Han, J., Sano, M., Davis, B. M., & Richards, H. M. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s57909 · Cited by 69
Alzheimer’s Disease: A Clinical Practice-Oriented Review
Alves, L., Correia, A. S., Miguel, R., Alegria, P., & Bugalho, P. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00063 · Cited by 74
Use of memantine for the treatment of dementia
Lo, D. T., & Grossberg, G. T. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.132 · Cited by 71
Pharmacological treatment of dementia
Schwarz, S. T., Froelich, L., & Burns, A. S. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328358e4f2 · Cited by 69
Long‐term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease
Zhu, C. W., Livote, E. E., Scarmeas, N., Albert, M., Brandt, J., Blacker, D., Sano, M. C., & Stern, Y. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.09.015 · Cited by 67
Development and Validation of the
Jeong, M. (2016) · Institute for Humanities and Social Sciences · doi:10.15818/ihss.2016.17.3.185 · Cited by 65
Stem cells and combination therapy for the treatment of traumatic brain injury
Dekmak, A., Mantash, S., Shaito, A. A., Toutonji, A., Ramadan, N., Ghazale, H., Kassem, N. A., Darwish, H., & Zibara, K. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.12.039 · Cited by 64
Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia
Koola, M. M., Buchanan, R. W., Pillai, A., Aitchison, K. J., Weinberger, D. R., Aaronson, S. T., & Dickerson, F. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.04.037 · Cited by 63
From Anti-Parkinson's Drug Rasagiline to Novel Multitarget Iron Chelators with Acetylcholinesterase and Monoamine Oxidase Inhibitory and Neuroprotective Properties for Alzheimer's Disease
Zheng, H., Amit, T., Bar‐Am, O., Fridkin, M., Youdim, M. B. H., & Mandel, S. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120013 · Cited by 62
An evaluation of memantine ER + donepezil for the treatment of Alzheimer’s disease
Calhoun, A. J., King, C., Khoury, R., & Grossberg, G. T. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1519022 · Cited by 62
Risk Factors That Affect Life Expectancy in Alzheimer's Disease: A 15-Year Follow-Up
Wattmo, C., Londos, E., & Minthon, L. (2014) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000362926 · Cited by 63
Rethinking Alzheimer's Disease Therapy: Are Mitochondria the Key?
Ankarcrona, M., Mangialasche, F., & Winblad, B. G. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100327 · Cited by 60
Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey
Vardigan, J. D., Cannon, C. E., Puri, V., Dancho, M., Koser, A. J., Wittmann, M., Kuduk, S. D., Renger, J. J., & Uslaner, J. M. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3813-x · Cited by 59
Mechanistic insights and emerging therapeutic stratagems for Alzheimer’s disease
Rajendran, K., & Krishnan, U. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102309 · Cited by 59
Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland
Taipale, H. T., Tanskanen, A. J., Koponen, M., Tolppanen, A., Tiihonen, J., & Hartikainen, S. A. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000032 · Cited by 56
Tracking Cognitive Change over 24 Weeks with Longitudinal Functional Magnetic Resonance Imaging in Alzheimer’s Disease
McLaren, D. G., Sreenivasan, A., Diamond, E. L., Mitchell, M. B., Dijk, K. R. A. V., DeLuca, A. N., O’Brien, J. L., Rentz, D. M., Sperling, R. A., & Atri, A. (2012) · Neurodegenerative Diseases · doi:10.1159/000335876 · Cited by 56
Self-citation
New and emerging treatments for Alzheimer’s disease
Corbett, A., Smith, J. S., & Ballard, C. G. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.43 · Cited by 58
Cholinesterase Inhibitor Therapy in Alzheimer’s Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates
Moss, D. E., Perez, R. G., & Kobayashi, H. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160733 · Cited by 55
Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study
Matsuzono, K., Hishikawa, N., Ohta, Y., Yamashita, T., Deguchi, K., Nakano, Y., & Abe, K. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-143084 · Cited by 55
Combination of drug and stem cells neurotherapy: Potential interventions in neurotrauma and traumatic brain injury
Zibara, K., Ballout, N., Mondello, S., Karnib, N., Ramadan, N., Omais, S., Nabbouh, A. I., Caliz, D., Clavijo, A., Hu, Z., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.09.032 · Cited by 52
Nasal delivery of neurotherapeutics via nanocarriers: Facets, aspects, and prospects
Rajput, A., Pingale, P., & Dhapte-Pawar, V. S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.979682 · Cited by 54
Curcumin: a natural substance with potential efficacy in Alzheimer’s disease
Potter, P. E. (2013) · Journal of Experimental Pharmacology · doi:10.2147/jep.s26803 · Cited by 51
The combination of memantine and galantamine improves cognition in rats: The synergistic role of the α7 nicotinic acetylcholine and NMDA receptors
Nikiforuk, A., Potasiewicz, A., Kos, T., & Popik, P. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.07.023 · Cited by 53
Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer’s Disease and Other Dementias
Muayqil, T. A., & Camicioli, R. M. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000343479 · Cited by 48
Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer’s Disease: Nexus of Cholinergic and Nerve Growth Factor Dysfunction
Moss, D. E., & Perez, R. G. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666211215150547 · Cited by 48
Memantine in Patients with Moderate to Severe Alzheimer's Disease: Meta-Analyses Using Realistic Definitions of Response
Wilkinson, D. G., Wirth, Y., & Goebel, C. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000353801 · Cited by 47
Efficacy and Safety of Donepezil 23 mg versus Donepezil 10 mg for Moderate-to-Severe Alzheimer’s Disease: A Subgroup Analysis in Patients Already Taking or Not Taking Concomitant Memantine
Doody, R. S., Geldmacher, D., Farlow, M. R., Sun, Y., Moline, M. L., & Mackell, J. A. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000338236 · Cited by 47
Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer’s disease: relevance for precision medicine in neurodegenerative diseases
Lista, S., Vergallo, A., Teipel, S. J., Lemercier, P., Giorgi, F. S., Gabelle, A., Garaci, F., Mercuri, N. B., Babiloni, C., Gaire, B. P., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101819 · Cited by 47
Neuropsychological Test Performance and Cognitive Reserve in Healthy Aging and the Alzheimer's Disease Spectrum: A Theoretically Driven Factor Analysis
Mitchell, M. B., Shaughnessy, L. W., Shirk, S. D., Yang, F. M., & Atri, A. (2012) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617712000859 · Cited by 49
Self-citation
Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer’s disease
Francis, P. T., Parsons, C. G., & Jones, R. W. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.124 · Cited by 47
Alzheimer Disease Pharmacologic Treatment and Treatment Research
Schneider, L. S. (2013) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000429180.60095.d0 · Cited by 45
Retrospective Study on the Benefits of Combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: The MEMAGE Study
Gareri, P., Putignano, D., Castagna, A., Cotroneo, A. M., Palo, G. D., Fabbo, A., Forgione, L., Giacummo, A., Lacava, R., Marino, S., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132735 · Cited by 42
Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer's disease
Chiu, M., & Fan, L. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s45143 · Cited by 41
The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia
Reiss, A. B., Raphael, D. D. L., Chin, N. A., & Sinha, V. (2022) · AIMS Public Health · doi:10.3934/publichealth.2022047 · Cited by 40
Improving Physician Awareness of Alzheimer Disease and Enhancing Recruitment
Galvin, J. E., Meuser, T. M., & Morris, J. C. (2011) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318212c0df · Cited by 40
Test-Retest Reliability of Memory Task Functional Magnetic Resonance Imaging in Alzheimer Disease Clinical Trials
Atri, A., O’Brien, J. L., Sreenivasan, A., Rastegar, S., Salisbury, S. L., DeLuca, A. N., O’Keefe, K., LaViolette, P. S., Rentz, D. M., Locascio, J. J., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.94 · Cited by 40
Self-citation
Efficacy and acceptability of anti-inflammatory eicosapentaenoic acid for cognitive function in Alzheimer’s dementia: A network meta-analysis of randomized, placebo-controlled trials with omega-3 fatty acids and FDA-approved pharmacotherapy
Tseng, P., Zeng, B., Suen, M., Wu, Y., Correll, C. U., Zeng, B., Kuo, J. S., Chen, Y.-W., Chen, T., Tu, Y.-K., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.04.017 · Cited by 39
Acupuncture for the Treatment of Alzheimer's Disease: An Overview of Systematic Reviews
Huang, J., Shen, M., Qin, X., Wu, M., Liang, S., & Huang, Y. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.574023 · Cited by 38
Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease
de Oliveira, F. F., Bertolucci, P. H. F., Chen, E., & Smith, M. D. A. C. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.10.015 · Cited by 36
Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine
Wong, C. W. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0372-3 · Cited by 37
Evaluation of Traditional Medicines for Neurodegenerative Diseases Using Drosophila Models
Lee, S., Bang, S. M., Lee, J. W., & Cho, K. S. (2014) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2014/967462 · Cited by 37
A Survey on Dementia Training Needs Among Staff at Community-Based Outpatient Clinics
Adler, G., Lawrence, B. M., Ounpraseuth, S., & Asghar‐Ali, A. A. (2015) · Educational Gerontology · doi:10.1080/03601277.2015.1071549 · Cited by 34
Coriandrum sativumSuppresses Aβ42-Induced ROS Increases, Glial Cell Proliferation, and ERK Activation
Liu, Q. F., Jeong, H., Lee, J. H., Hong, Y. K., Oh, Y., Kim, Y., Suh, Y. S., Bang, S. M., Yun, H. S., Lee, K., et al. (2016) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x16500749 · Cited by 34
Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
Seltzer, B. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s4819 · Cited by 32
Combined treatment with memantine/es‐citalopram for older depressed patients with cognitive impairment: a pilot study
Pelton, G. H., Harper, O. L., Roose, S. P., Marder, K. S., D’Antonio, K., & Devanand, D. P. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4375 · Cited by 32
Current neuroimaging techniques in Alzheimer's disease and applications in animal models.
Zhang, L., Chang, R. C., Chu, L., & Mak, H. K. (2012) · Europe PMC (PubMed Central) · Cited by 31
Pathogenic Feed-Forward Mechanisms in Alzheimer’s and Parkinson’s Disease Converge on GSK-3
Albeely, A. M., Ryan, S. D., & Perreault, M. L. (2018) · Brain Plasticity · doi:10.3233/bpl-180078 · Cited by 33
Cost-Effectiveness of Magnetic Resonance Imaging with a New Contrast Agent for the Early Diagnosis of Alzheimer's Disease
Biasutti, M., Dufour, N., Ferroud, C., Dab, W., & Temime, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035559 · Cited by 33

Authors: Atri, A., Shaughnessy, L. W., Locascio, J. J., & Growdon, J. H.
Affiliations: Harvard University (US)
Corresponding author: Atri, Alireza
Shaughnessy, Lynn W.
Locascio, Joseph J.
Growdon, John H.
ORCID: Atri, Alireza
Locascio, Joseph J.
Venue: Alzheimer Disease & Associated Disorders
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2008-07
Volume: 22
Issue: 3
Pages: 209-221
ISSN: 0893-0341 (ISSN-L)
DOI: 10.1097/wad.0b013e31816653bc
PMC: PMC2718545
OpenAlex: W2133239607
Cited by: 230
References: 54
Citations by year: 2026: 3 · 2025: 3 · 2024: 10 · 2023: 7 · 2022: 14 · 2021: 2 · 2020: 8 · 2019: 6 · 2018: 10 · 2017: 8 · 2016: 14 · 2015: 20 · 2014: 15 · 2013: 21 · 2012: 33
FWCI: 12.88
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Alzheimer Disease & Associated Disorders (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Massachusetts General Hospital
National Institute on Aging (5P50AG05134, 1K23 AG27171-01, K23AG027171, P50AG005134)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords: Alzheimer's disease, combination therapy, cholinesterase inhibitors, memantine, cognitive decline, functional decline, activities of daily living, long-term treatment effectiveness, real-world clinical outcomes, treatment duration
MeSH terms: Activities of Daily Living, Aged, Alzheimer Disease, Cholinesterase Inhibitors, Cognition, Cognition Disorders, Drug Therapy, Combination, Female, Humans, Male, Memantine, Time, Dopamine Agents, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Long-term Course and Effectiveness of Combination Therapy in Alzheimer Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks